FDA Approves Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 Vaccine
Pfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read moreThe unique OptoDrum device for automated in vivo assessment of visual performance in mice and rats offers unmatched capabilities for
Read moreSangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read moreThe cutting-edge AcuiSee device for visual acuity testing of laboratory animals stands out as a breakthrough in the realm of
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read moreA research study has showcased the use of Cellendes’ advanced 3-D Life Hydrogel products in developing an immunocompetent, PDMS-free organ-on-chip
Read moreJohnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read morePfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read moreThe 3-D Life RGD Peptide is a highly purified peptide designed specifically to enhance cell adhesion within 3-D hydrogel matrices.
Read moreCellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read more